News for Verona Pharma plc (VRNA)

Market Analysis by covering: Merck & Company Inc, Procter & Gamble Health Ltd, Verona Pharma PLC ADR. Read 's Market Analysis on Investing.com

PR NewswireNEW YORK, July 21, 2025 NEW YORK, July 21, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following co

NEW YORK, July 19, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations o

Does Verona Pharma PLC American Depositary Share (VRNA) have what it takes to be a top stock pick for momentum investors? Let's find out.

We came across a bullish thesis on Verona Pharma plc (VRNA) on Capital Employed’s  Substack by Patients Capital Management. In this article, we will summarize the bulls’ thesis on VRNA.

NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations o

Merck (MRK, Financials) is spending $10 billion to acquire U.K.-based Verona Pharma, the company announced Wednesday; the move is part of Merck's push to divers

PR NewswireNEW YORK, July 14, 2025 NEW YORK, July 14, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following co

In the latest analyst update, Verona Pharma (VRNA) has experienced a shift in rating and price target adjustments from HC Wainwright & Co. The updated informati

H.C. Wainwright analyst Raghuram Selvaraju has adjusted his rating for Verona Pharma (VRNA), downgrading the stock from Buy to Neutral. The revision comes after

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Verona Pharma plc (NASDAQ:VRNA) is one of the stocks Jim Cramer recently discussed. Verona Pharma plc (NASDAQ:VRNA) is a small biotechnology company that focuses on respiratory diseases. Its shares rocketed by 20.6% in July after pharma giant Merck announced that […]

On July 10, 2025, Verona Pharma (VRNA) received a significant update from Wells Fargo analyst Tiago Fauth. The analyst downgraded the stock from a previous rati

Verona Pharma (VRNA) has experienced a downgrade from Piper Sandler, moving from an Overweight to a Neutral rating. This adjustment accompanies the reduction of

In recent stock market developments, Verona Pharma (VRNA) has received a notable rating downgrade from the investment firm BTIG. On July 10, 2025, analyst Thoma

Verona Pharma plc (NASDAQ:VRNA) is one of the 10 Stocks Going Wild. Verona Pharma surged by 20.62 percent on Wednesday to end at $104.77 per share following news that it was being acquired by US-based pharmaceutical company Merck for $10 billion. In a statement, Merck said that it entered into a definitive agreement with Verona Pharma […]

Roth Capital analyst Boobalan Pachaiyappan has revised his outlook on Verona Pharma (VRNA), changing the rating from Buy to Neutral. The price target has also b

Verona Pharma plc (NASDAQ:VRNA) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds. Piper Sandler increased the price target on the company’s stock to $160 from $76, while maintaining an “Overweight” rating. The analyst highlighted that the Street anticipates Ohtuvayre to reach blockbuster status in 2027 with strong growth as […]

Merck & Co., Inc. (MRK) acquired Verona Pharma plc (VRNA) for $10 billion, boosting Verona’s shares by over 20% to $104.77, with the deal centered on Verona’s first-in-class COPD drug Ohtuvayre. Ohtuvayre, a novel inhaled therapy approved 13 months ago, generated $71.3 million in Q1 2025 sales with 95% sequential…